Related Experiment Video
Updated: Apr 10, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Elevated circulating unsaturated fatty acids: A novel metabolic feature of coronary artery disease without
Zijian Wang1,2, Xue Li2,3, Tao Hu2
1Department of Cardiology, Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
Insights
Coronary artery disease (CAD) patients without traditional risk factors show altered unsaturated fatty acid (UFA) metabolism. Elevated UFAs may serve as novel biomarkers for predicting CAD risk in this population.
Area of Science:
- Metabolomics
- Biochemistry
- Cardiovascular Disease Research
Background:
- Coronary artery disease (CAD) is a leading global cause of death.
- Many CAD patients lack conventional risk factors, indicating a residual risk.
- Identifying novel biomarkers for this subgroup is crucial for prevention.
Purpose of the Study:
- To investigate potential metabolomic biomarkers for residual risk in CAD patients without traditional risk factors.
- To explore the role of dysregulated metabolism in CAD pathogenesis in this specific population.
Main Methods:
- Untargeted metabolomic profiling of serum using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS).
- Comparative analysis between CAD patients lacking conventional risk factors and non-CAD controls.
- Pathway analysis to identify enriched metabolic pathways.
Main Results:
- Significant alterations in metabolite levels were observed in CAD patients.
- 43 metabolites were elevated and 46 were reduced compared to controls.
- A marked upregulation of circulating unsaturated fatty acids (UFAs) was identified, suggesting dysregulated UFA biosynthesis.
Conclusions:
- Dysregulated unsaturated fatty acid metabolism may play a role in CAD pathogenesis.
- Elevated circulating UFAs represent a novel metabolic signature in CAD patients without conventional risk factors.
- These UFAs could serve as potential predictive biomarkers for noninvasive risk stratification and targeted prevention, requiring further validation.
Abstract:
Coronary artery disease (CAD) remains a major cause of global mortality. While established risk factors are targets of effective preventive interventions, a substantial proportion of CAD patients exhibit no conventional risk factors. To investigate potential metabolomic biomarkers of residual risk in such individuals, we conducted untargeted metabolomic profiling of serum from CAD patients lacking traditional risk factors using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Comparative analysis with non-CAD controls revealed significant alterations in metabolite levels, with 43 metabolites elevated and 46 reduced in CAD patients. Notably, we observed a marked upregulation of circulating unsaturated fatty acids (UFAs) which reflects dysregulated unsaturated fatty acid biosynthesis. Pathway analysis further indicated enrichment in biosynthetic pathways of unsaturated fatty acids, implicating a potential role of dysregulated UFA metabolism in CAD pathogenesis. These altered fatty acids may act as potential biomarkers and residual risk factors for predicting CAD in individuals without conventional risk factors. Collectively, our study identifies elevated circulating UFAs as a novel metabolic signature in this patient subgroup, which may serve as a potential predictive indicator for noninvasive risk stratification and targeted prevention. To our knowledge, this is one of the initial metabolomic studies to identify UFA dysregulation in CAD patients without conventional risk factors, and the clinical utility requires further validation in larger multi-center cohorts.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Peripheral Artery Disease I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
